Deep and Durable Responses to Double Anti-BCMA, Single-Domain Antibody CAR-T Therapies Seen in RRMM
CAR-T therapy containing 2 anti-BCMA single-domain antibodies resulted in high response and PFS rates, according to phase 1b results.
Multiple Myeloma News
MULTIPLE MYELOMA ADVISOR
Multiple Myeloma News
Anti-BCMA CAR-T Deemed Effective in Heavily Pretreated, Refractory Multiple Myeloma
Anti-BCMA CAR T-cell therapy idecabtagene vicleucel demonstrated promising efficacy among patients with heavily pretreated and refractory MM.
Real-World Data Suggest Prolonged Lenalidomide Maintenance Therapy Is Beneficial in Patients With MRD-Positive Multiple Myeloma
Findings from this study support use of serial MRD monitoring during lenalidomide maintenance therapy to identify patients likely to benefit from prolonged treatment.
Novel Therapies Needed: Poor Prognosis of Patients With TP53-Mutated Myeloid Malignancies
Novel treatment options are needed to improve outcomes for patients with TP53-mutated myeloid neoplasms.
Prognostic Value of Immunomodulator in Higher-Risk Myelodysplastic Syndromes Treated With Azacitidine
Immunomodulator indoleamine-2,3-dioxygenase may be a promising predictor and therapeutic target for patients with higher-risk myelodysplastic syndromes.
Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
Autologous Stem Cell Transplantation Outcomes in Multiple Myeloma vs Non-Hodgkin Lymphoma
Higher graft CD34+ cell content is linked to improved platelet and neutrophil recovery after high-dose therapy.
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
SF3B1 Mutation in Clonal Cytopenia of Undetermined Significance Strongly Linked to Myelodysplastic Syndrome Development
Given the prevalence, the IWG-PM evaluated available evidence to determine whether SF3B1-mutated MDS should be recognized as a distinct disease subtype.
Tocilizumab Shows Benefit in a Patient With COVID-19 and Multiple Myeloma
IL-6 blockade may have helped a patient with multiple myeloma recover from COVID-19, but larger studies are needed to prove efficacy.
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Approaches to the Management of Older Patients With Multiple Myeloma During the COVID-19 Crisis
Guidance is provided regarding possible treatment plan alterations for older patients with multiple myeloma based on COVID-19 infection risk.
Subcutaneous Formulation of Daratumumab Approved for Multiple Myeloma
Darzalex Faspro is a new subcutaneous formulation that contains daratumumab, a CD38-directed cytolytic antibody, with hyaluronidase, an endoglycosidase.
What Factors Influence Hematological Recovery in Patients Who Receive CAR-T Therapies?
Two studies characterize hematological recovery after CAR-T cell therapy.
Gene-Expression Profiling Assay Predicts Survival in Newly Diagnosed Multiple Myeloma
The SKY92 MMprofiler assay evaluates the expression of 92 multiple myeloma-related genes.
Multiple Myeloma Scorecard: Efficacy, Cost, and Safety
New study compares published data from various treatment regimens for multiple myeloma, scoring them on efficacy, cost, and adverse effects.
Real-World Trends in the Assessment of Minimum Residual Disease in B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma
In recent years, the NCCN has updated its clinical practice guidelines to include MRD assessment for MM, ALL, and CLL.
Second Cancers Pose Significant Mortality Risk in Myeloproliferative Neoplasms
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
Increased Risk of Venous Thromboembolism in Patients With Myelofibrosis
One finding from this study was that VTE was more likely to occur at atypical sites in patients with myelofibrosis compared to those without the disease.
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma News
